<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7501082\results\search\disease\results.xml">
  <result pre="10.1016/j.bcp.2020.114225114225 : Perspective Role of proteolytic enzymes in the COVID-19" exact="infection" post="and promising therapeutic approaches GioiaMagdaaâ�ŽCiaccioChiaraaâ�ŽCalligariPaolobDe SimoneGiovannacSbardellaDiegodTundoGraziadFasciglioneGiovanni FrancescoaDi MasiAlessandracDi PierroDonatoaBocediAlessiobAscenziPaoloceColettaMassimoaâ�Ž[a],"/>
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Fall of 2019 a sudden and dramatic outbreak of a" exact="pulmonary" post="disease (Coronavirus Disease COVID-19), due to a new Coronavirus"/>
  <result pre="of 2019 a sudden and dramatic outbreak of a pulmonary" exact="disease" post="(Coronavirus Disease COVID-19), due to a new Coronavirus strain"/>
  <result pre="a sudden and dramatic outbreak of a pulmonary disease (Coronavirus" exact="Disease" post="COVID-19), due to a new Coronavirus strain (i.e., SARS-CoV-2),"/>
  <result pre="to now several hundreds of thousand deaths. As for common" exact="viral" post="infections, the crucial event for the viral life cycle"/>
  <result pre="As for common viral infections, the crucial event for the" exact="viral" post="life cycle is the entry of genetic material inside"/>
  <result pre="by host proteases; this is followed by translation of the" exact="viral" post="RNA into a polyprotein, exploiting the host cell machinery."/>
  <result pre="exploiting the host cell machinery. The production of individual mature" exact="viral" post="proteins is pivotal for replication and release of new"/>
  <result pre="concerted fashion to regulate and coordinate specific steps of the" exact="viral" post="replication and assembly, such as (i) the entry of"/>
  <result pre="compounds designed to impair this vicious cycle. Abbreviations COVID-19, Coronavirus" exact="Disease" post="â€&quot; 19 SARS-CoV, Severe Acute Respiratory Syndrome coronavirus SARS-CoV-2,"/>
  <result pre="this vicious cycle. Abbreviations COVID-19, Coronavirus Disease â€&quot; 19 SARS-CoV," exact="Severe" post="Acute Respiratory Syndrome coronavirus SARS-CoV-2, Severe Acute Respiratory Syndrome"/>
  <result pre="vicious cycle. Abbreviations COVID-19, Coronavirus Disease â€&quot; 19 SARS-CoV, Severe" exact="Acute" post="Respiratory Syndrome coronavirus SARS-CoV-2, Severe Acute Respiratory Syndrome â€&quot;"/>
  <result pre="cycle. Abbreviations COVID-19, Coronavirus Disease â€&quot; 19 SARS-CoV, Severe Acute" exact="Respiratory" post="Syndrome coronavirus SARS-CoV-2, Severe Acute Respiratory Syndrome â€&quot; 2"/>
  <result pre="Abbreviations COVID-19, Coronavirus Disease â€&quot; 19 SARS-CoV, Severe Acute Respiratory" exact="Syndrome" post="coronavirus SARS-CoV-2, Severe Acute Respiratory Syndrome â€&quot; 2 MERS-CoV,"/>
  <result pre="Disease â€&quot; 19 SARS-CoV, Severe Acute Respiratory Syndrome coronavirus SARS-CoV-2," exact="Severe" post="Acute Respiratory Syndrome â€&quot; 2 MERS-CoV, Middle East Respiratory"/>
  <result pre="â€&quot; 19 SARS-CoV, Severe Acute Respiratory Syndrome coronavirus SARS-CoV-2, Severe" exact="Acute" post="Respiratory Syndrome â€&quot; 2 MERS-CoV, Middle East Respiratory Syndrome"/>
  <result pre="19 SARS-CoV, Severe Acute Respiratory Syndrome coronavirus SARS-CoV-2, Severe Acute" exact="Respiratory" post="Syndrome â€&quot; 2 MERS-CoV, Middle East Respiratory Syndrome coronavirus"/>
  <result pre="SARS-CoV, Severe Acute Respiratory Syndrome coronavirus SARS-CoV-2, Severe Acute Respiratory" exact="Syndrome" post="â€&quot; 2 MERS-CoV, Middle East Respiratory Syndrome coronavirus ORF,"/>
  <result pre="SARS-CoV-2, Severe Acute Respiratory Syndrome â€&quot; 2 MERS-CoV, Middle East" exact="Respiratory" post="Syndrome coronavirus ORF, Open Reading Frame PLpro, Papain-like protease"/>
  <result pre="Severe Acute Respiratory Syndrome â€&quot; 2 MERS-CoV, Middle East Respiratory" exact="Syndrome" post="coronavirus ORF, Open Reading Frame PLpro, Papain-like protease Mpro,"/>
  <result pre="Binding Domain PC, Pro-protein Convertase HCoV-OC43, Human Coronavirus-OC43 MHV-A59, Murine" exact="Hepatitis" post="virus â€&quot; A59 HIV, Human Immunodeficiency virus CMK, Chloro-Methyl-Ketone"/>
  <result pre="Human Coronavirus-OC43 MHV-A59, Murine Hepatitis virus â€&quot; A59 HIV, Human" exact="Immunodeficiency" post="virus CMK, Chloro-Methyl-Ketone Dec, Decanoyl Phac, Phenyl-Acetyl TTSP, Type"/>
  <result pre="Human Immunodeficiency virus CMK, Chloro-Methyl-Ketone Dec, Decanoyl Phac, Phenyl-Acetyl TTSP," exact="Type II" post="Transmembrane Serine Proteases family HPV, Human Papillomavirus HBV, Hepatitis"/>
  <result pre="Type II Transmembrane Serine Proteases family HPV, Human Papillomavirus HBV," exact="Hepatitis" post="B virus EVD, Ebola VirusÂ Disease ZIKV, Zika virus"/>
  <result pre="HPV, Human Papillomavirus HBV, Hepatitis B virus EVD, Ebola VirusÂ" exact="Disease" post="ZIKV, Zika virus JEV, Japanese Encephalitis virus FPV, Feline"/>
  <result pre="B virus EVD, Ebola VirusÂ Disease ZIKV, Zika virus JEV," exact="Japanese Encephalitis" post="virus FPV, Feline Panleukopenia virus HPAIV, Highly Pathogenic Avian"/>
  <result pre="virus EVD, Ebola VirusÂ Disease ZIKV, Zika virus JEV, Japanese" exact="Encephalitis" post="virus FPV, Feline Panleukopenia virus HPAIV, Highly Pathogenic Avian"/>
  <result pre="Japanese Encephalitis virus FPV, Feline Panleukopenia virus HPAIV, Highly Pathogenic" exact="Avian" post="Influenza virus CDV, Canine Distemper virus RSV, Respiratory Syncytial"/>
  <result pre="Highly Pathogenic Avian Influenza virus CDV, Canine Distemper virus RSV," exact="Respiratory" post="Syncytial virusÂ (RSV) A1AT, Alpha-1-Anti Trypsin AEBSF, 4-(2-aminomethyl)-benzene sulphonyl"/>
  <result pre="BHH, BromHexine Hydrochloride PCSK, Pro-protein Convertase Subtilisin/Kexin AMPK, Adenosine Monophosphate-activated" exact="Protein" post="Kinase HCoV-NL63, Human Coronavirus â€&quot; NL63 HCoV-229E, Human Coronavirus"/>
  <result pre="2013 and SARS-CoV-2 in 2019, which have been associated with" exact="acute" post="severe respiratory illnesses. As of September 8, SARS-CoV-2 virus,"/>
  <result pre="SARS-CoV-2 in 2019, which have been associated with acute severe" exact="respiratory" post="illnesses. As of September 8, SARS-CoV-2 virus, responsible for"/>
  <result pre="community has come together to understand the mechanisms underlying the" exact="infection" post="and the virulence of SARS-CoV-2 virus, as well as"/>
  <result pre="Currently, there is neither antiviral nor vaccine for the severe" exact="acute" post="respiratory syndrome induced by SARS-CoV-2. Its alarming spread and"/>
  <result pre="there is neither antiviral nor vaccine for the severe acute" exact="respiratory" post="syndrome induced by SARS-CoV-2. Its alarming spread and its"/>
  <result pre="is neither antiviral nor vaccine for the severe acute respiratory" exact="syndrome" post="induced by SARS-CoV-2. Its alarming spread and its severity"/>
  <result pre="for the elucidation of the pathogenetic features of this novel" exact="viral infection" post="in search for effective therapeutic approaches [1]. Little is"/>
  <result pre="the elucidation of the pathogenetic features of this novel viral" exact="infection" post="in search for effective therapeutic approaches [1]. Little is"/>
  <result pre="crucial similarities between SARS-CoV-2 and other members of the same" exact="viral" post="order (i.e., Nidovirales) [2]. Hence, to rapidly gain insights"/>
  <result pre="what we have learned from several medicinal chemistry studies on" exact="viral" post="spreading to help us in finding promising targets for"/>
  <result pre="the development of anti-viral strategies for SARS-CoV-2. 1.1 Host and" exact="viral" post="proteases involved in viral life-cycle As for common viral"/>
  <result pre="strategies for SARS-CoV-2. 1.1 Host and viral proteases involved in" exact="viral" post="life-cycle As for common viral infections, the crucial event"/>
  <result pre="and viral proteases involved in viral life-cycle As for common" exact="viral" post="infections, the crucial event for the viral life cycle"/>
  <result pre="As for common viral infections, the crucial event for the" exact="viral" post="life cycle is the entry of genetic material inside"/>
  <result pre="life-cycle, SARS-CoV-2 is internalized in the host cell where the" exact="viral" post="RNA is translated, exploiting the host cell machinery and"/>
  <result pre="frames (ORF)s. The ORF1, which encompasses about 75% of the" exact="viral" post="genome, is translated into two viral replicase polyproteins (i.e.,"/>
  <result pre="about 75% of the viral genome, is translated into two" exact="viral" post="replicase polyproteins (i.e., pp1a and pp1ab) (Fig. 1 )."/>
  <result pre="development of anti-viral strategies The activity of several endoproteases ensures" exact="viral infection," post="involving host and viral proteases which belong to the"/>
  <result pre="activity of several endoproteases ensures viral infection, involving host and" exact="viral" post="proteases which belong to the classes of serine- and"/>
  <result pre="concerted fashion to regulate and coordinate specific steps of the" exact="viral" post="propagation, such as (i) the entry and the replication"/>
  <result pre="). Fig. 2 Diagram of the involvement of host and" exact="viral" post="proteases in SARS-CoV-2 life cycle. Activation of coronavirus spike"/>
  <result pre="by host cell proteases occurs at different stages in the" exact="viral" post="life cycle and in different cell localizations. The ACE2-dependent"/>
  <result pre="viral life cycle and in different cell localizations. The ACE2-dependent" exact="infectious" post="entry at the cell membrane is triggered through the"/>
  <result pre="in trans-Golgi network (TGN) (4). After the receptor recognition, the" exact="viral" post="genome is released into the cytoplasm of the host"/>
  <result pre="shown). Polyprotein (pp) maturation into mature fragments is catalysed by" exact="viral" post="Cys proteases (Mpro and PL pro) (6). RNA is"/>
  <result pre="replication amplifies the number of virus genome copies (7). The" exact="viral" post="genome produces pps, which help to take command over"/>
  <result pre="(8). The virion assembly occurs (9) and the newly packed" exact="viral" post="particles can egress (10). The spike glycoproteins are responsible"/>
  <result pre="A), playing a crucial role for the entry of the" exact="viral" post="genome inside the host cell (Fig. 2). The first"/>
  <result pre="of proteolytic events leading to the fusion of cell and" exact="viral" post="membranes. Similarity in structure and sequence with SARS-CoV and"/>
  <result pre="Schematic representation of coronavirus particle. Spike proteins are highly glycosylated" exact="type I" post="transmembrane protein, which assemble into trimers on the virion"/>
  <result pre="[9], [13]. Thus, to activate the fusion machinery of the" exact="viral" post="S protein the cooperation in space and in time"/>
  <result pre="for each cell type). Among host proteases, involved in the" exact="viral infection," post="furin is the one most widely present, being constitutively"/>
  <result pre="also detected linked to the membrane of oral and airway" exact="epithelial" post="cells [16], [15]. Unlike close relatives, SARS-CoV-2 can promptly"/>
  <result pre="lung cells to endothelial, conjunctival and gut cells, with the" exact="respiratory" post="district being the main target, displaying the peculiar ability"/>
  <result pre="main target, displaying the peculiar ability to infect even the" exact="upper" post="respiratory tract. The efficient spreading of virus relies on"/>
  <result pre="target, displaying the peculiar ability to infect even the upper" exact="respiratory" post="tract. The efficient spreading of virus relies on the"/>
  <result pre="protease arsenal of host cells which mediate the propagation of" exact="viral infection." post="The expression profile of furin and ACE2 in human"/>
  <result pre="idea that this enzyme plays a dominant relevance in SARS-CoV-2" exact="viral infection" post="[13], [19], [20], [21]. Therefore, furin may play either"/>
  <result pre="that this enzyme plays a dominant relevance in SARS-CoV-2 viral" exact="infection" post="[13], [19], [20], [21]. Therefore, furin may play either"/>
  <result pre="located. A key discovery in understanding the mechanism of SARS-CoV-2" exact="infection" post="concerns the role of the androgen-responsive transmembrane serine protease"/>
  <result pre="transmembrane serine protease 2 (TMPRSS2), that is expressed by specific" exact="epithelial" post="tissues (including those of the respiratory and digestive tracts),"/>
  <result pre="is expressed by specific epithelial tissues (including those of the" exact="respiratory" post="and digestive tracts), facilitating the SARS-CoV-2 entry in the"/>
  <result pre="the SARS-CoV-2 entry in the human airways by cleaving the" exact="viral" post="spike (S) protein [22], [23], [19] (Fig. 2). Beside"/>
  <result pre="[22], [23], [19] (Fig. 2). Beside host proteolytic enzymes, two" exact="viral" post="proteases, namely Mpro and PLpro (involved in the maturation"/>
  <result pre="proteases, namely Mpro and PLpro (involved in the maturation of" exact="viral" post="polyprotein) are also recognized as important drug target(s). In"/>
  <result pre="has been found to play a prominent role in the" exact="viral" post="gene expression and replication, thus becoming an attractive target"/>
  <result pre="Î²-barrel structure, which has a folding scaffold similar to other" exact="viral" post="chymotrypsin-like proteases. However, unlike chymotrypsin, the active site of"/>
  <result pre="evolutionary analyses indicate that SARS-CoV-2 Mpro is a highly conserved" exact="viral" post="protein, which recognizes the sequence Leu-Met-Phe-Glnâ†&quot;Ser-Gly-Ala while no human"/>
  <result pre="target for a broad inhibition of multiple stages in the" exact="viral" post="life cycle (such as viral formation, progression of the"/>
  <result pre="of multiple stages in the viral life cycle (such as" exact="viral" post="formation, progression of the viral infection and reproduction of"/>
  <result pre="viral life cycle (such as viral formation, progression of the" exact="viral infection" post="and reproduction of virions). Overall, two very attractive processes"/>
  <result pre="life cycle (such as viral formation, progression of the viral" exact="infection" post="and reproduction of virions). Overall, two very attractive processes"/>
  <result pre="S protein (by furin and TMPRRS2), impairing the entry of" exact="viral" post="genetic material inside the host cell, and (b) the"/>
  <result pre="material inside the host cell, and (b) the activity of" exact="viral" post="proteases (in particular Mpro), impairing the formation of mature"/>
  <result pre="viral proteases (in particular Mpro), impairing the formation of mature" exact="viral" post="proteins, which are required for the progression of the"/>
  <result pre="viral proteins, which are required for the progression of the" exact="viral infection" post="and replication of viruses. 2 Activation of spike (S)"/>
  <result pre="proteins, which are required for the progression of the viral" exact="infection" post="and replication of viruses. 2 Activation of spike (S)"/>
  <result pre="viruses. 2 Activation of spike (S) protein by host proteases" exact="Multiple" post="cleavages of coronavirus S protein are the primary determinants"/>
  <result pre="host proteases Multiple cleavages of coronavirus S protein are the" exact="primary" post="determinants of the viral tropism, since this protein is"/>
  <result pre="of coronavirus S protein are the primary determinants of the" exact="viral" post="tropism, since this protein is responsible for receptor binding"/>
  <result pre="binding and, once cleaved, it drives the fusion of the" exact="viral" post="envelope with the cell membrane. 2.1 Structure-function of S"/>
  <result pre="This large glycoprotein (approx. 180Â kDa) is present on the" exact="viral" post="surface as a prominent trimer, each monomer ectodomain being"/>
  <result pre="a large ectodomain, a single pass transmembrane anchor, and a" exact="short" post="C-terminal intracellular tail [26], showing several conserved domains and"/>
  <result pre="[26] (Fig. 3B). The globular N-terminal S1 subunit mediates the" exact="infection" post="of receptor-expressing host cells; it contains a receptor-binding domain"/>
  <result pre="highly conserved fusion peptide, important for the entry of the" exact="viral" post="genome inside the host. Multiple cleavage events activate the"/>
  <result pre="for the entry of the viral genome inside the host." exact="Multiple" post="cleavage events activate the viral S protein with the"/>
  <result pre="viral genome inside the host. Multiple cleavage events activate the" exact="viral" post="S protein with the involvement of several host proteases;"/>
  <result pre="to the lipid transmembrane and it is involved in the" exact="viral" post="entry [30]. It contains the fusion peptide (FP), followed"/>
  <result pre="L have also been shown to be involved in SARS-CoV-2" exact="infection" post="[20], [11]. The formation of the S2 fragment and"/>
  <result pre="virion membrane and forming a pore for the passageway of" exact="viral" post="material inside the cytoplasm. 2.2 Cell receptor binding through"/>
  <result pre="much higher (about 6â€&quot;20-fold) affinity than what reported for other" exact="viral" post="Spike proteins (KDÂ ~Â 15Â nM, as from [33],"/>
  <result pre="of the S protein for ACE2 and partially impairing the" exact="viral" post="invasion in lung and small intestine epithelial cells, where"/>
  <result pre="partially impairing the viral invasion in lung and small intestine" exact="epithelial" post="cells, where ACE2 is mostly expressed [37]. 3 Host"/>
  <result pre="expressed in eukaryotic cells and tissues [10]. Furin is a" exact="type I" post="transmembrane highly specific endoprotease which cleaves the precursor forms"/>
  <result pre="triad and of the binding sites of furin to the" exact="viral" post="S protein are displayed. (C): Crystal structure of mouse"/>
  <result pre="Furin inhibitors Because of the key role of furin in" exact="cancer" post="and several infectious diseases, including Human Immunodeficiency virus (HIV)"/>
  <result pre="of the key role of furin in cancer and several" exact="infectious diseases," post="including Human Immunodeficiency virus (HIV) and coronaviruses [44], [14],"/>
  <result pre="of furin in cancer and several infectious diseases, including Human" exact="Immunodeficiency" post="virus (HIV) and coronaviruses [44], [14], its suitability as"/>
  <result pre="Refs. Î±1-PDX 600 Prevents the processing of HIV-1 gp160 and" exact="measles" post="virus-Fo in vitro. [38], [46], [47] Limits joint inflammation"/>
  <result pre="joint inflammation when delivered with adenovirus into the joint of" exact="arthritic" post="mice. [176] Dec-Arg-Val-Lys-Arg-CMK 1000 Topical uses in the treatment"/>
  <result pre="particles. [19] Phac-Arg-Val-Arg-Amba 810 Reduces FPV propagation in a long-term" exact="infection" post="test. [61] Suppresses the activation of HA0 in fowl"/>
  <result pre="infection test. [61] Suppresses the activation of HA0 in fowl" exact="plague" post="virus in cell-based assays. [61] MI-1148 5.5 Protective effect"/>
  <result pre="affinity) and to prevent the processing of HIVâ€�1 Env and" exact="measles" post="virus F in vitro[38], [46], [47] (see Table 1)."/>
  <result pre="its efficacy [54]. Dec-Arg-Val-Lys-Arg-CMK is effective in the reduction of" exact="hepatitis" post="B virus (HBV) replication by inhibiting furin-mediated processing of"/>
  <result pre="B virus (HBV) replication by inhibiting furin-mediated processing of the" exact="hepatitis" post="B e antigen (HBeAg) precursor into mature HBeAg [55]."/>
  <result pre="is able to inhibit furin-mediated cleavage and fusion activity of" exact="viral" post="glycoproteins, and acts as an antiviral agent against different"/>
  <result pre="agent against different viruses, including HIV [44], Chikungunya virus [56]," exact="chronic" post="HBV, influenza A, Ebola virus infection [55] and papilloma"/>
  <result pre="HIV [44], Chikungunya virus [56], chronic HBV, influenza A, Ebola" exact="virus infection" post="[55] and papilloma virus [57]. Recently, the efficacy of"/>
  <result pre="[44], Chikungunya virus [56], chronic HBV, influenza A, Ebola virus" exact="infection" post="[55] and papilloma virus [57]. Recently, the efficacy of"/>
  <result pre="[56], chronic HBV, influenza A, Ebola virus infection [55] and" exact="papilloma" post="virus [57]. Recently, the efficacy of dec-Arg-Val-Lys-Arg-CMK as an"/>
  <result pre="of dec-Arg-Val-Lys-Arg-CMK as an anti-flavivirus agent (against Zika virus and" exact="Japanese encephalitis" post="virus) has been demonstrated in both mammalian cells and"/>
  <result pre="dec-Arg-Val-Lys-Arg-CMK as an anti-flavivirus agent (against Zika virus and Japanese" exact="encephalitis" post="virus) has been demonstrated in both mammalian cells and"/>
  <result pre="in terms of the reduction in virus progeny titre, in" exact="viral" post="RNA and protein production [58]. In the context of"/>
  <result pre="CMK moiety, the potential therapeutic applications of these molecules remain" exact="limited" post="to topical applications, such as the treatment of papillomavirus"/>
  <result pre="topical applications, such as the treatment of papillomavirus (HPV) skin" exact="infections" post="[53], [45]. However, the incorporation of amino acid analogues,"/>
  <result pre="assay, as an inhibitor of the cleavage of the fowl" exact="plague" post="hemagglutinin of the H7 subtypes of the avian influenza"/>
  <result pre="the fowl plague hemagglutinin of the H7 subtypes of the" exact="avian influenza" post="viruses, possessing a multi-basic furin cleavage site; this limited"/>
  <result pre="avian influenza viruses, possessing a multi-basic furin cleavage site; this" exact="limited" post="efficacy might be related to a reduced ability of"/>
  <result pre="able to reduce feline panleukopenia virus propagation in a long-term" exact="infection" post="test (25Â Î¼M of inhibitor over a period of"/>
  <result pre="MI-1148 was shown to have a significant protective effect against" exact="anthrax" post="and diphtheria toxin and to be active against H5N1"/>
  <result pre="shown to have a significant protective effect against anthrax and" exact="diphtheria" post="toxin and to be active against H5N1 and H7N1"/>
  <result pre="diphtheria toxin and to be active against H5N1 and H7N1" exact="avian influenza" post="viruses (HPAIV) and canine distemper viruses (CDV) propagation in"/>
  <result pre="tested as inhibitors of the proteolytic activation and replication of" exact="respiratory" post="syncytial virusÂ in cells [63] (see Table 1). Significant"/>
  <result pre="Structure-function A key discovery in understanding the mechanism of SARS-CoV-2" exact="infection" post="concerns the role of the androgen-responsive transmembrane serine protease"/>
  <result pre="the SARS-CoV-2 entry in the human airways by cleaving the" exact="viral" post="Spike (S) protein [22], [23], [19]. TMPRSS2 (EC 3.4.21.109)"/>
  <result pre="[23], [19]. TMPRSS2 (EC 3.4.21.109) is preferentially expressed in several" exact="epithelial" post="tissues, such as prostate, kidney, colon, small intestine, pancreas,"/>
  <result pre="it has been demonstrated that the expression of TMPRSS2 in" exact="lung cancer" post="cell line A549 and prostate cancer cell is androgen-dependent"/>
  <result pre="has been demonstrated that the expression of TMPRSS2 in lung" exact="cancer" post="cell line A549 and prostate cancer cell is androgen-dependent"/>
  <result pre="expression of TMPRSS2 in lung cancer cell line A549 and" exact="prostate cancer" post="cell is androgen-dependent [22], [65], [66]. TMPRSS2 is also"/>
  <result pre="of TMPRSS2 in lung cancer cell line A549 and prostate" exact="cancer" post="cell is androgen-dependent [22], [65], [66]. TMPRSS2 is also"/>
  <result pre="of fact, among the clinical complications of COVIDâ€�19 myocardial and" exact="acute" post="kidney injuries are reported together with gastrointestinal symptoms [67],"/>
  <result pre="TMPRSS2 is also expressed in microvascular endothelial cells of the" exact="blood vessels," post="the SARSâ€�CoVâ€�2 virus may bring about endothelial dysfunction with"/>
  <result pre="the SARSâ€�CoVâ€�2 virus may bring about endothelial dysfunction with associated" exact="thrombosis" post="[70], [68]. Notably, epidemiological studies, carried out in several"/>
  <result pre="and severity of the diagnosis of COVID-19 and other TMPRSS2-dependent" exact="viral" post="infections are higher in men than in women. In"/>
  <result pre="severity of the diagnosis of COVID-19 and other TMPRSS2-dependent viral" exact="infections" post="are higher in men than in women. In this"/>
  <result pre="in women. In this regard, the role of TMPRSS2 in" exact="prostate cancer" post="and the androgen-dependent TMPRSS2 expression has led to speculate"/>
  <result pre="women. In this regard, the role of TMPRSS2 in prostate" exact="cancer" post="and the androgen-dependent TMPRSS2 expression has led to speculate"/>
  <result pre="predicted protein of 492 amino acids that belongs to the" exact="type II" post="transmembrane serine proteases (TTSPs) family [74], [75]. The TTSP"/>
  <result pre="step, which involves the formation of a covalently linked enzyme-peptide" exact="intermediate" post="and the loss of a peptide fragment, followed by"/>
  <result pre="the deacylation step, characterized by a nucleophilic attack on the" exact="intermediate" post="by water, leading to the hydrolysis of the peptide"/>
  <result pre="involved in the proteolytic activation of influenza virus (cleaving the" exact="viral" post="hemoagglutinin A) and coronavirus (cleaving the viral Spike (S)"/>
  <result pre="virus (cleaving the viral hemoagglutinin A) and coronavirus (cleaving the" exact="viral" post="Spike (S) protein), thus contributing to the virus invasion"/>
  <result pre="mesylate, partially inhibits the entry of SARS-CoV-2 into the lung" exact="epithelial" post="cells [84], [19], [15]. Furthermore, TMPRSS2-deficient mice had minimal"/>
  <result pre="cells [84], [19], [15]. Furthermore, TMPRSS2-deficient mice had minimal initial" exact="infection" post="when infected with specific influenza A virus strains, SARS-CoV"/>
  <result pre="A virus strains, SARS-CoV and MERS-CoV, respectively, showing an attenuated" exact="disease" post="progression, as compared to wild type control mice. This"/>
  <result pre="progeny virus and consequently inhibition of virus spread along the" exact="respiratory" post="tract [85], [86], [87], [88]. Of note, although the"/>
  <result pre="proteolytic priming (see Fig. 2), only TMPRSS2 is essential for" exact="viral" post="spread and pathogenicity (cathepsin B/L activity being dispensable) [89],"/>
  <result pre="[90]. In this regard, it has been demonstrated that the" exact="transient" post="expression of TMPRSS2 in Vero cells favors the cathepsin-independent"/>
  <result pre="SARS-CoV-2 S protein show that both cleavage sites of the" exact="viral" post="S protein (i.e., S1/S2 site and S2â€², see Fig."/>
  <result pre="(Arg685/Ser686), the TMPRSS2 His296 establishes a hydrogen bond with the" exact="viral" post="S protein residue Arg682; (ii) at the second cleavage"/>
  <result pre="levels (0.9Â g/L), its concentration displaying a six-fold increase under" exact="acute" post="inflammation [93]. In the lungs, A1AT acts as a"/>
  <result pre="further, AEBSF partially inhibits also the fusion of the mouse" exact="hepatitis" post="coronavirus [95]. Bromhexine hydrochloride (BHH) is a drug used"/>
  <result pre="adverse effects, it could be used for treatment of coronavirus" exact="infections" post="as an inhibitor of TMPRSS2 [64], [66], [92]. Camostat"/>
  <result pre="Similarly, the Nafamostat, a structural analog of Camostat, blocks SARS-CoV-2" exact="infection" post="of human lung cells with 15-fold higher efficiency than"/>
  <result pre="backbone acceptor. Asp187 forms an acidic hydrogen bond with the" exact="primary" post="amine and a sidechain donor hydrogen bond with the"/>
  <result pre="primary amine and a sidechain donor hydrogen bond with the" exact="secondary" post="amine of the ligand [76]. In addition, different groups"/>
  <result pre="SARS-CoV-2 pandemia, showing its own peculiar protein targets. In the" exact="absence of" post="an effective vaccine, inhibitor repurposing or de novo drug"/>
  <result pre="an interesting potential antiviral strategy concerns the inhibition of ACE2-dependent" exact="viral" post="entry, interfering with the cleavage of SARS-CoV-2 spike protein"/>
  <result pre="with the cleavage of SARS-CoV-2 spike protein to arrest the" exact="viral" post="propagation. 3.3.1 Therapeutic platform for furin Within the lineage"/>
  <result pre="and in vivo efficacy of furin inhibitors, there is very" exact="limited" post="clinical trial evidence to support or reject the use"/>
  <result pre="cellular processes [99], an important issue would be to avoid" exact="systemic" post="inhibition that may lead to relevant side effects. While"/>
  <result pre="Although a selective inhibition of individual PCSKs can be achieved," exact="systemic" post="longâ€�term inhibition will most likely have detrimental effects. Therefore,"/>
  <result pre="the therapeutic application of furin inhibitors is to limit the" exact="systemic" post="inhibition that may lead to some adverse effects. It"/>
  <result pre="some adverse effects. It must be stressed that, differently from" exact="viral" post="targets, furin (like any protein hijacked by the virus"/>
  <result pre="cleavage of glycoprotein does not result in a reduction of" exact="viral" post="replication under cell culture conditions, suggesting that the inhibition"/>
  <result pre="additional proofs-of-concept are required at each step of the different" exact="infectious" post="processes. An additional important aspect concerns the assessment of"/>
  <result pre="enhance their efficacy [101], [54]. A possible strategy to limit" exact="viral" post="infections is the restriction of the trafficking of furin"/>
  <result pre="their efficacy [101], [54]. A possible strategy to limit viral" exact="infections" post="is the restriction of the trafficking of furin to"/>
  <result pre="despite the crucial role of furin, it is possible that" exact="acute" post="inhibition over a limited time interval may lead to"/>
  <result pre="of furin, it is possible that acute inhibition over a" exact="limited" post="time interval may lead to vastly beneficial effects in"/>
  <result pre="time interval may lead to vastly beneficial effects in tackling" exact="viral" post="infections, especially in the case of a substantial ineffectiveness"/>
  <result pre="the central role of TMPRSS2 in activating SARS-CoV-2 and other" exact="respiratory" post="viral infections, to interfere on its expression or on"/>
  <result pre="central role of TMPRSS2 in activating SARS-CoV-2 and other respiratory" exact="viral" post="infections, to interfere on its expression or on its"/>
  <result pre="its activity indeed could represent a promising approach to treat" exact="respiratory" post="COVID-19. Therefore, the knowledge of the amino acids that"/>
  <result pre="this TMPRSS2 inhibitor should be validated for treatment of coronavirus" exact="infection" post="as it does not show toxicity in humans, since"/>
  <result pre="of 0.01â€&quot;1Â Âµg/ml) inhibit the coronavirus replication in human airway" exact="epithelial" post="cells, displaying an additive effect in combination with interferon"/>
  <result pre="cleaved into 16 different non-structural proteins (nsp) by the two" exact="viral" post="proteases (i.e., Mpro and PLpro). The N-terminal part, which"/>
  <result pre="deubiquitination of host polyubiquitin chains and the formation of the" exact="viral" post="double-vesicles membranes (see Fig. 1). The rest of pp1a"/>
  <result pre="(b) Betacoronavirus (i.e., (i) HCoV-OC43, (ii) HCoV-HKU1, (iii) the severe" exact="acute" post="respiratory syndrome SARS-CoV, and (iv) the Middle East respiratory"/>
  <result pre="Betacoronavirus (i.e., (i) HCoV-OC43, (ii) HCoV-HKU1, (iii) the severe acute" exact="respiratory" post="syndrome SARS-CoV, and (iv) the Middle East respiratory syndrome"/>
  <result pre="(i.e., (i) HCoV-OC43, (ii) HCoV-HKU1, (iii) the severe acute respiratory" exact="syndrome" post="SARS-CoV, and (iv) the Middle East respiratory syndrome MERS-CoV)"/>
  <result pre="severe acute respiratory syndrome SARS-CoV, and (iv) the Middle East" exact="respiratory" post="syndrome MERS-CoV) [108]. The multiple-sequence alignment of the main"/>
  <result pre="acute respiratory syndrome SARS-CoV, and (iv) the Middle East respiratory" exact="syndrome" post="MERS-CoV) [108]. The multiple-sequence alignment of the main proteases"/>
  <result pre="below), where substitutions occur quite often during the evolution of" exact="viral" post="Mpro proteins [109]. Fig. 6 Analysis of sequence and"/>
  <result pre="HCoV-OC43 (P0C6U7), HCoV-KU1 (P0C6U3), MERS-CoV (V9TU05), HCoV-NL63 (P0C6U6), HCoV-229E (P0C6U2)." exact="Secondary" post="structure references were taken from SARS-CoV-2 Mpro (PDB: 6M2Q)."/>
  <result pre="is referred to the web version of this article.) 4.1.2" exact="Structural" post="features of Mpro proteases in SARS-CoV-2 In the mature"/>
  <result pre="is also worth noting that, while the autocatalytic process of" exact="viral" post="polyproteins is performed by both Mpro and PLpro, the"/>
  <result pre="SARS-CoV sequence) flanking the S1 pocket [116]. Interestingly, a particularly" exact="stable" post="water molecule seems also to play an important role"/>
  <result pre="protein, the â€œN-fingerâ€� (the N-terminal residues) of each monomer forms" exact="stable" post="hydrogen bonds with Phe140 and Glu166 of the other"/>
  <result pre="that, despite the high sequence/structure similarity, their active site binding" exact="cavities" post="have significantly different shape with an overall accessible volume"/>
  <result pre="only protease that processes the post translational maturation of the" exact="viral" post="polypeptide product but there is also a papain-like protease"/>
  <result pre="binding of ligands to the PLpro but not the overall" exact="secondary" post="and tertiary structures, suggesting that inhibitors developed for SARS-CoV"/>
  <result pre="recognizes the tetrapeptide Lys-Xxx-Gly-Gly motif at P4-P1 positions found in-between" exact="viral" post="non-structural proteins (i.e., ns1 and 2, ns2 and 3,"/>
  <result pre="but the P3 and P4 sites are almost identical. 4.3" exact="Viral" post="protease inhibition An efficient inhibition of a multimeric protease"/>
  <result pre="6lu7) was released to public on February 2020 through the" exact="Protein" post="Data Bank [124]. N3 inhibitor (N-[(5-methylisoxazol-3-yl)carbonyl]alanyl-L-valyl-NÂ ~Â 1~-((1R,2Z)-4-(benzyloxy)-4-oxo-1-{[(3R)-2-oxopyrrolidin-3-yl]methyl}but-2-enyl)-L-leucinamide) was"/>
  <result pre="=Â 0.040Â Î¼M, respectively), being also effective on the anti-SARS-CoV-2" exact="infection" post="activity in cell culture (EC50Â =Â 0.53Â Î¼M and"/>
  <result pre="with antibiotic properties and administered for the treatment of Mycobacterium" exact="tuberculosis" post="infection, was docked for Mpro embedding deeply inside the"/>
  <result pre="kcal/mol) (Fig. 7F) a drug used for the treatment of" exact="insomnia" post="[151]. Further, the antibiotic talampicillin and the anti-psychotic lurasidone"/>
  <result pre="umifenovir, together with montelukast, a drug for the treatment of" exact="allergies" post="and the prevention of asthma attacks, showed moderate binding"/>
  <result pre="drug for the treatment of allergies and the prevention of" exact="asthma" post="attacks, showed moderate binding score to Mpro (âˆ’6.5Â kcal/mol"/>
  <result pre="Mpro (âˆ’6.5Â kcal/mol andÂ âˆ’Â 6.5Â kcal/mol, respectively) while a" exact="lower" post="score was found for chloroquine and hydroxychloroquine with âˆ’5.0Â"/>
  <result pre="and their applications. Inhibitor EC50 (ÂµM) Application Refs. Baicalin 27.87" exact="Respiratory" post="tract infection [154] Baicalein 2.94 Respiratory tract infection [154]"/>
  <result pre="applications. Inhibitor EC50 (ÂµM) Application Refs. Baicalin 27.87 Respiratory tract" exact="infection" post="[154] Baicalein 2.94 Respiratory tract infection [154] Chloroquine 2.71/5.47"/>
  <result pre="Application Refs. Baicalin 27.87 Respiratory tract infection [154] Baicalein 2.94" exact="Respiratory" post="tract infection [154] Chloroquine 2.71/5.47 Malaria [155], [162] Hydroxychloroquine"/>
  <result pre="Baicalin 27.87 Respiratory tract infection [154] Baicalein 2.94 Respiratory tract" exact="infection" post="[154] Chloroquine 2.71/5.47 Malaria [155], [162] Hydroxychloroquine 0.7/4.51 Malaria"/>
  <result pre="infection [154] Baicalein 2.94 Respiratory tract infection [154] Chloroquine 2.71/5.47" exact="Malaria" post="[155], [162] Hydroxychloroquine 0.7/4.51 Malaria [162], [155] Remdesivir 23.15"/>
  <result pre="tract infection [154] Chloroquine 2.71/5.47 Malaria [155], [162] Hydroxychloroquine 0.7/4.51" exact="Malaria" post="[162], [155] Remdesivir 23.15 Ebolavirus [161] Boceprevir 1.31 HCV"/>
  <result pre="Cinanserin 20.61 SARS [124] Lopinavir 26.63 HIV [161] Homorringtonine 2.55" exact="Chronic" post="myeloid leukemia [161] Emetine hydrochloride 0.46 Amoebiasis [161] A"/>
  <result pre="20.61 SARS [124] Lopinavir 26.63 HIV [161] Homorringtonine 2.55 Chronic" exact="myeloid leukemia" post="[161] Emetine hydrochloride 0.46 Amoebiasis [161] A second study"/>
  <result pre="SARS [124] Lopinavir 26.63 HIV [161] Homorringtonine 2.55 Chronic myeloid" exact="leukemia" post="[161] Emetine hydrochloride 0.46 Amoebiasis [161] A second study"/>
  <result pre="[161] Homorringtonine 2.55 Chronic myeloid leukemia [161] Emetine hydrochloride 0.46" exact="Amoebiasis" post="[161] A second study displayed a variety of different"/>
  <result pre="EC50 of 1.31Â Î¼M against the SARS-CoV-2 virus in the" exact="primary" post="viral cytopathic effect (CPE) assay. An interesting result was"/>
  <result pre="of 1.31Â Î¼M against the SARS-CoV-2 virus in the primary" exact="viral" post="cytopathic effect (CPE) assay. An interesting result was obtained"/>
  <result pre="global inhibitory function on NF-kB signalling and inflammatory responses during" exact="viral infection" post="[158]. Cinanserin was considered an inhibitor of SARS-CoV (IC50Â"/>
  <result pre="inhibitory function on NF-kB signalling and inflammatory responses during viral" exact="infection" post="[158]. Cinanserin was considered an inhibitor of SARS-CoV (IC50Â"/>
  <result pre="emetine at 0.195Â Î¼M achieved more than 60% inhibition in" exact="viral" post="yield. The conclusion is that a â€œcocktailâ€� of antiviral"/>
  <result pre="antiviral drugs may reduce compound concentrations and increase inhibition of" exact="viral" post="replication [161]. Finally, chloroquine and hydroxychloroquine both inhibit SARS-CoV-2"/>
  <result pre="=Â 5.47Â Î¼M vs 0.7Â Î¼M in the Vero cell" exact="infection" post="model, respectively) [162], though displaying suboptimal affinity scores ofÂ"/>
  <result pre="Mpro, in particular its mechanism of action and involvement in" exact="viral" post="replication, does not rule out the possibility that it"/>
  <result pre="clinical observation clarifies that mortality is increased by co-morbidities like" exact="cardiovascular disease," post="hypertension, diabetes, chronic pulmonary disease, and cancer. The therapies"/>
  <result pre="mortality is increased by co-morbidities like cardiovascular disease, hypertension, diabetes," exact="chronic" post="pulmonary disease, and cancer. The therapies with antiviral drugs"/>
  <result pre="is increased by co-morbidities like cardiovascular disease, hypertension, diabetes, chronic" exact="pulmonary" post="disease, and cancer. The therapies with antiviral drugs may"/>
  <result pre="short-term use of chloroquine/hydroxychloroquine, ribavirin, and lopinavir/ritonavir in patients without" exact="autoimmune diseases," post="hepatitis, HIV infection is not clear. Remdesivir is an"/>
  <result pre="chloroquine/hydroxychloroquine, ribavirin, and lopinavir/ritonavir in patients without autoimmune diseases, hepatitis," exact="HIV infection" post="is not clear. Remdesivir is an experimental drug for"/>
  <result pre="ribavirin, and lopinavir/ritonavir in patients without autoimmune diseases, hepatitis, HIV" exact="infection" post="is not clear. Remdesivir is an experimental drug for"/>
  <result pre="is an experimental drug for the treatment of Ebolavirus, so" exact="cardiovascular" post="effects and toxicities are unknown, whereas chloroquine/hydroxychloroquine seem to"/>
  <result pre="and toxicities are unknown, whereas chloroquine/hydroxychloroquine seem to have considerable" exact="cardiovascular" post="effects, at least when used at high dosage [165]."/>
  <result pre="SARS-CoV-2 infection, discouraging its use at the later stage of" exact="viral infection;" post="further, lopinavir/ritonavir showed side-effects, such as nausea, diarrhoea and"/>
  <result pre="trial of hydroxychloroquine or lopinavir/ritonavir suggested their use in severe" exact="pneumonia" post="and critically ill children [168]. The chloroquine and hydroxychloroquine,"/>
  <result pre="ill children [168]. The chloroquine and hydroxychloroquine, originally employed for" exact="malaria" post="treatment, deserve a further clarification, since they should block"/>
  <result pre="deserve a further clarification, since they should block the SARS-CoV-2" exact="viral" post="entry into cells by elevation of endosomal pH and"/>
  <result pre="and chloroquine have certain limitations and toxicity, especially on the" exact="heart" post="and eyes. Considering their ocular, cardiac and neuro toxicities,"/>
  <result pre="remdesivir was not associated with statistically significant clinical benefits in" exact="adult" post="patients with severe COVID-19, but a larger study will"/>
  <result pre="a non-randomized study of 67 patients, affected by COVID-19, a" exact="lower" post="mortality rate was shown to occur in patients treated"/>
  <result pre="a protease inhibitor itself and inhibits membrane fusion of the" exact="viral" post="envelope by targeting the interaction of the S protein"/>
  <result pre="ACE2. Favipiravir, an anti-influenza drug approved in Japan, interferes with" exact="viral" post="replication and it is a potential inhibitor of RNA-dependent"/>
  <result pre="of a great effort worldwide, current drugs have only a" exact="limited" post="efficacy in treating COVID-19; on the other hand, given"/>
  <result pre="hand, given the high rate of infectivity of SARS-CoV-2 with" exact="diffuse" post="lethal effects, especially in immunocompromised patients, the design of"/>
  <result pre="new drugs targeting specific activities of the virus and its" exact="infection" post="cycle is essential [175]. Considerable progress has been made"/>
  <result pre="compounds to â€˜druggableâ€™ molecules with improved power and stability profiles." exact="Combined" post="with novel delivery technologies, peptide-based drugs can be addressed"/>
  <result pre="emergence of resistant strains under drug selective pressure and their" exact="limited" post="availability in high-risk cases further exacerbates the need for"/>
  <result pre="usually employed to verify the proof of principle of the" exact="viral infection" post="process. However, it may not usually be practical, demanding"/>
  <result pre="employed to verify the proof of principle of the viral" exact="infection" post="process. However, it may not usually be practical, demanding"/>
  <result pre="a number of drawbacks, such as the need of the" exact="viral" post="genome, expensive synthesizing processes, availability of monoclonal antibodies, and"/>
  <result pre="focus on host proteases involved in the entry of the" exact="viral" post="genome. Thus, exploring the cellular factors, employed by SARS-CoV-2"/>
  <result pre="SARS-CoV-2 for entry, might result in providing useful information about" exact="viral" post="outbreak and a number of therapeutic approaches. Further, while"/>
  <result pre="while targeting the intracellular virus cycle does not avoid the" exact="infection" post="of cells (only impairing the further diffusion of virions),"/>
  <result pre="targeting instead host proteases, involved in the entry of the" exact="viral" post="genome, means to block the onset itself of the"/>
  <result pre="viral genome, means to block the onset itself of the" exact="viral" post="attack. In this respect, SARS-CoV-2 cell entry, which relies"/>
  <result pre="entry, which relies on ACE-2, furin and TMPRSS2 can be" exact="limited" post="by protease inhibitors [19]. Therefore, furin and TMPRSS2 inhibitors"/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChemBioChem.21202073073810.1002/cbic.20200004732022370 2ChenY.LiuQ.GuoD.Emerging Coronaviruses: genome structure,"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChemBioChem.21202073073810.1002/cbic.20200004732022370 2ChenY.LiuQ.GuoD.Emerging Coronaviruses: genome structure, replication,"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChemBioChem.21202073073810.1002/cbic.20200004732022370 2ChenY.LiuQ.GuoD.Emerging Coronaviruses: genome structure, replication, and"/>
  <result pre="2ChenY.LiuQ.GuoD.Emerging Coronaviruses: genome structure, replication, and pathogenesisJ. Med. Virol.92202041842310.1002/jmv.2568131967327 3BredenbeekP.J.PachukC.J.NotenA.F.ChariteJ.LuytjesW.WeissS.R.SpaanW.J.The" exact="primary" post="structure and expression of the second open reading frame"/>
  <result pre="by an efficient ribosomal frameshifting mechanismNucl. Acids Res.1819901825183210.1093/nar/18.7.18252159623 4LeeH.J.ShiehC.K.GorbalenyaA.E.KooninE.V.La MonicaN.TulerJ.BagdzhadzhyanA.LaiM.M.The" exact="complete" post="sequence (22 kilobases) of murine coronavirus gene 1 encoding"/>
  <result pre="for proteolytic activation and spread of SARS-CoV-2 in human airway" exact="epithelial" post="cells and provide promising drug targetsBioRxiv202010.1101/2020.04.15.042085 16LinB.ZhongM.GaoH.WuK.LiuM.LiuC.WangX.ChenJ.LeeL.QiC.GeL.WangL.Significant expression of"/>
  <result pre="drug targetsBioRxiv202010.1101/2020.04.15.042085 16LinB.ZhongM.GaoH.WuK.LiuM.LiuC.WangX.ChenJ.LeeL.QiC.GeL.WangL.Significant expression of FURIN and ACE2 on oral" exact="epithelial" post="cells may facilitate the efficiency of 2019-nCov entryBioRxiv202010.1101/2020.04.18.04795 17D."/>
  <result pre="the coronavirus pandemic, Nature 581 (2020) 22â€&quot;26, doi: 10.1038/d41586-020-01315-7. 18ZhouP.YangX.-L.WangX.-G.HuB.ZhangL.ZhangW.SiH.-R.ZhuY.LiB.HuangC.-L.ChenH.-D.ChenJ.LuoY.GuoH.JiangR.-D.LiuM.-Q.ChenY.ShenX.-R.WangX.ZhengX.-S.ZhaoK.ChenQ.-J.DengF.LiuL.-L.YanB.ZhanF.-X.WangY.-Y.XiaoG.-F.ShiZ.-L.A" exact="pneumonia" post="outbreak associated with a new coronavirus of probable bat"/>
  <result pre="of the cellular entry of the coronavirus mediated by the" exact="viral" post="protein of the peak virusViruses46June 20121011103310.3390/v406101122816037 31BelouzardS.ChuV.C.WhittakerG.R.Activation of the"/>
  <result pre="Natl Acad. Sci. USA10620095871587610.1073/pnas.080952410619321428 32MilletJ.K.WhittakerG.R.Host cell entry of Middle East" exact="respiratory" post="syndrome coronavirus after two-step, furin-mediated activation of the spike"/>
  <result pre="Acad. Sci. USA10620095871587610.1073/pnas.080952410619321428 32MilletJ.K.WhittakerG.R.Host cell entry of Middle East respiratory" exact="syndrome" post="coronavirus after two-step, furin-mediated activation of the spike proteinProc."/>
  <result pre="prevents Furin-catalyzed activation of the fusion glycoprotein and production of" exact="infectious" post="measles virusJ. Virol.691995320632107707552 47DufourE.K.DenaultJ.B.HopkinsP.C.LeducR.Serpin-like properties of alpha1-antitrypsin Portland towards"/>
  <result pre="Furin-catalyzed activation of the fusion glycoprotein and production of infectious" exact="measles" post="virusJ. Virol.691995320632107707552 47DufourE.K.DenaultJ.B.HopkinsP.C.LeducR.Serpin-like properties of alpha1-antitrypsin Portland towards Furin"/>
  <result pre="convertaseFEBS Lett.4261998414610.1016/s0014-5793(98)00307-x9598975 48ShiryaevS.A.RemacleA.G.RatnikovB.I.NelsonN.A.SavinovA.Y.WeiG.BottiniM.RegaM.F.ParentA.DesjardinsR.FugereM.DayR.SabetM.PellecchiaM.LiddingtonR.C.SmithJ.W.MustelinT.GuineyD.G.LeblM.StronginA.Y.Targeting host proteinases as a therapeutic strategy against" exact="viral" post="and bacterial pathogensJ. Biol. Chem.2822007208472085310.1074/jbc.M70384720017537721 49CameronA.AppelJ.HoughtenR.A.LindbergI.Polyarginines are potent Furin"/>
  <result pre="48ShiryaevS.A.RemacleA.G.RatnikovB.I.NelsonN.A.SavinovA.Y.WeiG.BottiniM.RegaM.F.ParentA.DesjardinsR.FugereM.DayR.SabetM.PellecchiaM.LiddingtonR.C.SmithJ.W.MustelinT.GuineyD.G.LeblM.StronginA.Y.Targeting host proteinases as a therapeutic strategy against viral and" exact="bacterial" post="pathogensJ. Biol. Chem.2822007208472085310.1074/jbc.M70384720017537721 49CameronA.AppelJ.HoughtenR.A.LindbergI.Polyarginines are potent Furin inhibitorsJ. Biol."/>
  <result pre="a small molecule inhibitorACS Chem. Biol.1220171211121610.1021/acschembio.6b0111028402100 52BraunE.SauterD.Furin-mediated protein processing in" exact="infectious diseases" post="and cancerClin. Transl. Immunol.82019e107310.1002/cti2.1073 53HenrichS.CameronA.BourenkovG.P.KiefersauerR.HuberR.LindbergI.BodeW.ThanM.E.The crystal structure of the"/>
  <result pre="peptidyl chloroalkyl ketonesVirology1721989253110.1016/0042-6822(89)90103-72773317 55PangY.J.TanX.J.LiD.M.ZhengZ.H.LeiR.X.PengX.M.Therapeutic potential of furin inhibitors for the" exact="chronic" post="infection of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya"/>
  <result pre="chloroalkyl ketonesVirology1721989253110.1016/0042-6822(89)90103-72773317 55PangY.J.TanX.J.LiD.M.ZhengZ.H.LeiR.X.PengX.M.Therapeutic potential of furin inhibitors for the chronic" exact="infection" post="of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya virus"/>
  <result pre="55PangY.J.TanX.J.LiD.M.ZhengZ.H.LeiR.X.PengX.M.Therapeutic potential of furin inhibitors for the chronic infection of" exact="hepatitis" post="B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya virus infection in"/>
  <result pre="the chronic infection of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of" exact="Chikungunya virus infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
  <result pre="chronic infection of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya" exact="virus infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
  <result pre="infection of hepatitis B virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya virus" exact="infection" post="in cultured human muscle cells by furin inhibitors: impairment"/>
  <result pre="virusLiver Int.3320131230123810.1111/liv.1218523617302 56OzdenS.Lucas-HouraniM.CeccaldiP.E.BasakA.ValentineM.BenjannetS.HamelinJ.JacobY.MamchaouiK.MoulyV.DesprÃ¨sP.GessainA.Butler-BrowneG.ChrÃ©tienM.TangyF.VidalainP.O.SeidahN.G.Inhibition of Chikungunya virus infection in cultured human" exact="muscle" post="cells by furin inhibitors: impairment of the maturation of"/>
  <result pre="Inhibition of proprotein convertases abrogates processing of the middle eastern" exact="respiratory" post="syndrome coronavirus spike protein in infected cells but does"/>
  <result pre="of proprotein convertases abrogates processing of the middle eastern respiratory" exact="syndrome" post="coronavirus spike protein in infected cells but does not"/>
  <result pre="coronavirus spike protein in infected cells but does not reduce" exact="viral" post="infectivity, J. Infect. Dis. 211 (2015) 889â€&quot;897, doi: 10.1093/infdis/jiu407."/>
  <result pre="site in the Spike protein of SARS-CoV-2 is essential for" exact="infection" post="of human lungCells, Molecular Cell.78202077978410.1016/j.molcel.2020.04.02232362314 61BeckerG.L.SielaffF.ThanM.E.LindbergI.RouthierS.DayR.LuY.GartenW.SteinmetzerT.Potent inhibitors of Furin"/>
  <result pre="protease TMPRSS2 activates a proteolytic cascade involving components of the" exact="tumor" post="microenvironment and promotes prostate cancer metastasisCancer Dis.420141310132510.1158/2159-8290.CD-13-1010 65MikkonenL.PihlajamaaP.SahuB.ZhangF.P.JÃ¤nneO.A.Androgen receptor"/>
  <result pre="proteolytic cascade involving components of the tumor microenvironment and promotes" exact="prostate cancer" post="metastasisCancer Dis.420141310132510.1158/2159-8290.CD-13-1010 65MikkonenL.PihlajamaaP.SahuB.ZhangF.P.JÃ¤nneO.A.Androgen receptor and androgen- dependent gene expression"/>
  <result pre="cascade involving components of the tumor microenvironment and promotes prostate" exact="cancer" post="metastasisCancer Dis.420141310132510.1158/2159-8290.CD-13-1010 65MikkonenL.PihlajamaaP.SahuB.ZhangF.P.JÃ¤nneO.A.Androgen receptor and androgen- dependent gene expression"/>
  <result pre="virus and coronavirus infectionsBiochimie142201711028778717 67MadjidM.Safavi-NaeiniP.SolomonS.D.VardenyO.Potential effects of coronaviruses on the" exact="cardiovascular" post="system: a reviewJAMA Cardiol.2020 68StropeJ.D.PharmaDC.H.C.FiggW.D.Potential biomarker for COVID-19 outcomesJ."/>
  <result pre="COVID-19 outcomesJ. Clin. Pharmacol.607202080180710.1002/jcph.164132437018 69PanX.W.XuD.ZhangH.ZhouW.WangL.H.CuiX.G.Identification of a potential mechanism of" exact="acute" post="kidney injury during the COVID-19 outbreak: a study based"/>
  <result pre="outcomesJ. Clin. Pharmacol.607202080180710.1002/jcph.164132437018 69PanX.W.XuD.ZhangH.ZhouW.WangL.H.CuiX.G.Identification of a potential mechanism of acute" exact="kidney injury" post="during the COVID-19 outbreak: a study based on single-cell"/>
  <result pre="TMPRSS2 and HAT are expressed at multiple sites in human" exact="respiratory" post="and gastrointestinal tractsPLoS One72012e3587610.1371/journal.pone.0035876 71StopsackK.H.MucciL.A.AntonarakisE.S.NelsonP.S.KantoffP.W.TMPRSS2 and COVID- 19: serendipity"/>
  <result pre="airway proteases TMPRSS2 and HAT differs in subcellular localization and" exact="susceptibility to" post="protease inhibitorsJ. Virol.8420105605561410.1128/JVI.00140-1020237084 82C. Chaipan, D. Kobasa, S. Bertram,"/>
  <result pre="83 (2009) 3200â€&quot;3211, doi: 10.1128/JVI.02205-08. 83MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe" exact="acute" post="respiratory syndrome coronavirus Spike protein by the transmembrane protease"/>
  <result pre="(2009) 3200â€&quot;3211, doi: 10.1128/JVI.02205-08. 83MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute" exact="respiratory" post="syndrome coronavirus Spike protein by the transmembrane protease TMPRSS2J."/>
  <result pre="3200â€&quot;3211, doi: 10.1128/JVI.02205-08. 83MatsuyamaS.NagataN.ShiratoK.KawaseM.TakedaM.TaguchiF.Efficient activation of the severe acute respiratory" exact="syndrome" post="coronavirus Spike protein by the transmembrane protease TMPRSS2J. Virol.842010126581266410.1128/JVI.01542-1020926566"/>
  <result pre="protease TMPRSS2J. Virol.842010126581266410.1128/JVI.01542-1020926566 84KawaseM.ShiratoK.van der HoekL.TaguchiF.MatsuyamaS.Simultaneous treatment of human bronchial" exact="epithelial" post="cells with serine and cysteine protease inhibitors prevents severe"/>
  <result pre="epithelial cells with serine and cysteine protease inhibitors prevents severe" exact="acute" post="respiratory syndrome coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 85HatesuerB.BertramS.MehnertN.BahgatM.M.NelsonP.S.PÃ¶hlmannS.SchughartK.TMPRSS2 is essential for"/>
  <result pre="cells with serine and cysteine protease inhibitors prevents severe acute" exact="respiratory" post="syndrome coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 85HatesuerB.BertramS.MehnertN.BahgatM.M.NelsonP.S.PÃ¶hlmannS.SchughartK.TMPRSS2 is essential for influenza"/>
  <result pre="with serine and cysteine protease inhibitors prevents severe acute respiratory" exact="syndrome" post="coronavirus entryJ. Virol.8620126537654510.1128/JVI.00094-1222496216 85HatesuerB.BertramS.MehnertN.BahgatM.M.NelsonP.S.PÃ¶hlmannS.SchughartK.TMPRSS2 is essential for influenza H1N1"/>
  <result pre="(2015) 76â€&quot;84, doi: 10.1016/j.antiviral.2015.01.011. 90RahmanN.BasharatZ.YousufM.CastaldoG.RastrelliL.KhanH.Virtual screening of natural products against" exact="type II" post="transmembrane serine protease (TMPRSS2), the priming agent of Coronavirus"/>
  <result pre="of TLR4/MyD88 pathway by geniposide suppresses HIF1-independent VEGF expression and" exact="hepatocellular carcinoma" post="angiogenesisBr. J. Pharmacol.17720203240325710.1111/bph.1504632144747 98HuangB.ChenP.HuangL.LiS.ZhuR.ShengT.YuW.ChenZ.WangT.Geniposide attenuates post-ischaemic neurovascular damage via"/>
  <result pre="TLR4/MyD88 pathway by geniposide suppresses HIF1-independent VEGF expression and hepatocellular" exact="carcinoma" post="angiogenesisBr. J. Pharmacol.17720203240325710.1111/bph.1504632144747 98HuangB.ChenP.HuangL.LiS.ZhuR.ShengT.YuW.ChenZ.WangT.Geniposide attenuates post-ischaemic neurovascular damage via"/>
  <result pre="the cell's master switchesBiochem. Pharmacol.140201781510.1016/j.bcp.2017.04.02728456517 103BassiD.E.ZhangJ.RennerC.Klein-SzantoA.J.Targeting proprotein convertases in furin-rich" exact="lung cancer" post="cells results in decreased in vitro and in vivo"/>
  <result pre="cell's master switchesBiochem. Pharmacol.140201781510.1016/j.bcp.2017.04.02728456517 103BassiD.E.ZhangJ.RennerC.Klein-SzantoA.J.Targeting proprotein convertases in furin-rich lung" exact="cancer" post="cells results in decreased in vitro and in vivo"/>
  <result pre="a natural productMolecules222017168910.3390/molecules22101689 105YamayaM.NishimuraH.DengX.KikuchiA.NagatomiR.Protease inhibitors: candidate drugs to inhibit severe" exact="acute" post="respiratory syndrome Coronavirus 2 replicationTohoku J. Exp. Med.2512020273010.1620/tjem.251.2732448818 106ColasantiM.PersichiniT.VenturiniG.AscenziP.S-nitrosylation"/>
  <result pre="natural productMolecules222017168910.3390/molecules22101689 105YamayaM.NishimuraH.DengX.KikuchiA.NagatomiR.Protease inhibitors: candidate drugs to inhibit severe acute" exact="respiratory" post="syndrome Coronavirus 2 replicationTohoku J. Exp. Med.2512020273010.1620/tjem.251.2732448818 106ColasantiM.PersichiniT.VenturiniG.AscenziP.S-nitrosylation of"/>
  <result pre="productMolecules222017168910.3390/molecules22101689 105YamayaM.NishimuraH.DengX.KikuchiA.NagatomiR.Protease inhibitors: candidate drugs to inhibit severe acute respiratory" exact="syndrome" post="Coronavirus 2 replicationTohoku J. Exp. Med.2512020273010.1620/tjem.251.2732448818 106ColasantiM.PersichiniT.VenturiniG.AscenziP.S-nitrosylation of viral"/>
  <result pre="respiratory syndrome Coronavirus 2 replicationTohoku J. Exp. Med.2512020273010.1620/tjem.251.2732448818 106ColasantiM.PersichiniT.VenturiniG.AscenziP.S-nitrosylation of" exact="viral" post="proteins: molecular bases for antiviral effect of nitric oxideIUBMB"/>
  <result pre="inhibitor designInt. J. Mol. Sci.212020309910.3390/ijms21093099 110YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.GaoG.F.AnandK.BartlamM.HilgenfeldR.RaoZ.The crystal structures of severe" exact="acute" post="respiratory syndrome virus main protease and its complex with"/>
  <result pre="designInt. J. Mol. Sci.212020309910.3390/ijms21093099 110YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.GaoG.F.AnandK.BartlamM.HilgenfeldR.RaoZ.The crystal structures of severe acute" exact="respiratory" post="syndrome virus main protease and its complex with an"/>
  <result pre="J. Mol. Sci.212020309910.3390/ijms21093099 110YangH.YangM.DingY.LiuY.LouZ.ZhouZ.SunL.MoL.YeS.PangH.GaoG.F.AnandK.BartlamM.HilgenfeldR.RaoZ.The crystal structures of severe acute respiratory" exact="syndrome" post="virus main protease and its complex with an inhibitorProc."/>
  <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370 122RutW.LvZ.ZmudzinskiM.PatchettS.NayakD.SnipasS.J.El OualidF.HuangT.T.BekesM.DragM.OlsenS.K.Activity profiling and"/>
  <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370 122RutW.LvZ.ZmudzinskiM.PatchettS.NayakD.SnipasS.J.El OualidF.HuangT.T.BekesM.DragM.OlsenS.K.Activity profiling and structures"/>
  <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoVChemBioChem21202073073810.1002/cbic.20200004732022370 122RutW.LvZ.ZmudzinskiM.PatchettS.NayakD.SnipasS.J.El OualidF.HuangT.T.BekesM.DragM.OlsenS.K.Activity profiling and structures of"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov.620201610.1038/s41421-020-0156-032194981 156MaC.SaccoM.D.HurstB.TownsendJ.A.HuY.SzetoT.ZhangX.TarbetB.MartyM.T.ChenY.WangJ.Boceprevir, GC-376, and calpain inhibitors II,"/>
  <result pre="Discov.620201610.1038/s41421-020-0156-032194981 156MaC.SaccoM.D.HurstB.TownsendJ.A.HuY.SzetoT.ZhangX.TarbetB.MartyM.T.ChenY.WangJ.Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2" exact="viral" post="replication by targeting the viral main proteaseCell Res.30202067869210.1038/s41422-020-0356-z32541865 157HungH.C.KeY.Y.HuangS.Y.HuangP.N.KungY.A.ChangT.Y.YenK.J.PengT.T.ChangS.E.HuangC.T.TsaiY.R.WuS.H.LeeS.J.LinJ.H.LiuB.S.SungW.C.ShihS.T.ChenC.T.HsuJ.T.Discovery"/>
  <result pre="inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the" exact="viral" post="main proteaseCell Res.30202067869210.1038/s41422-020-0356-z32541865 157HungH.C.KeY.Y.HuangS.Y.HuangP.N.KungY.A.ChangT.Y.YenK.J.PengT.T.ChangS.E.HuangC.T.TsaiY.R.WuS.H.LeeS.J.LinJ.H.LiuB.S.SungW.C.ShihS.T.ChenC.T.HsuJ.T.Discovery of M Protease Inhibitors Encoded"/>
  <result pre="against COVID-19BioRxiv202010.1101/2020.03.23.004580 159YangQ.ChenL.HeX.GaoZ.ShenX.BaiD.Design and synthesis of cinanserin analogs as severe" exact="acute" post="respiratory syndrome coronavirus 3CL protease inhibitorsChem. Pharm. Bull. (Tokyo)5620081400140510.1248/cpb.56.140018827378"/>
  <result pre="COVID-19BioRxiv202010.1101/2020.03.23.004580 159YangQ.ChenL.HeX.GaoZ.ShenX.BaiD.Design and synthesis of cinanserin analogs as severe acute" exact="respiratory" post="syndrome coronavirus 3CL protease inhibitorsChem. Pharm. Bull. (Tokyo)5620081400140510.1248/cpb.56.140018827378 160ChenL.GuiC.LuoX.YangQ.GÃ¼ntherS.ScandellaE.DrostenC.BaiD.HeX.LudewigB.ChenJ.LuoH.YangY.YangY.ZouJ.ThielV.ChenK.ShenJ.ShenX.JiangH.Cinanserin"/>
  <result pre="159YangQ.ChenL.HeX.GaoZ.ShenX.BaiD.Design and synthesis of cinanserin analogs as severe acute respiratory" exact="syndrome" post="coronavirus 3CL protease inhibitorsChem. Pharm. Bull. (Tokyo)5620081400140510.1248/cpb.56.140018827378 160ChenL.GuiC.LuoX.YangQ.GÃ¼ntherS.ScandellaE.DrostenC.BaiD.HeX.LudewigB.ChenJ.LuoH.YangY.YangY.ZouJ.ThielV.ChenK.ShenJ.ShenX.JiangH.Cinanserin is"/>
  <result pre="160ChenL.GuiC.LuoX.YangQ.GÃ¼ntherS.ScandellaE.DrostenC.BaiD.HeX.LudewigB.ChenJ.LuoH.YangY.YangY.ZouJ.ThielV.ChenK.ShenJ.ShenX.JiangH.Cinanserin is an inhibitor of the 3C-like proteinase of severe" exact="acute" post="respiratory syndrome coronavirus and strongly reduces virus replication in"/>
  <result pre="is an inhibitor of the 3C-like proteinase of severe acute" exact="respiratory" post="syndrome coronavirus and strongly reduces virus replication in vitroJ."/>
  <result pre="an inhibitor of the 3C-like proteinase of severe acute respiratory" exact="syndrome" post="coronavirus and strongly reduces virus replication in vitroJ. Virol.791120057095710310.1128/JVI.79.11.7095-7103.200515890949"/>
  <result pre="of Optimized Dosing Design of Hydroxychloroquine for the Treatment of" exact="Severe" post="Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis."/>
  <result pre="Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe" exact="Acute" post="Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71(15)"/>
  <result pre="Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute" exact="Respiratory" post="Syndrome Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71(15) (2020),"/>
  <result pre="Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory" exact="Syndrome" post="Coronavirus 2 (SARS-CoV-2). Clin. Infect. Dis. 71(15) (2020), 732â€&quot;739."/>
  <result pre="of human coronavirus papain-like proteasesJ. Med. Chem.5720142393241210.1021/jm401712t24568342 165GuzikT.J.MohiddinS.A.DimarcoA.PatelV.SavvatisK.Marelli-BergF.M.MadhurM.S.TomaszewskiM.MaffiaP.D'AcquistoF.NicklinS.A.MarianA.J.NosalskiR.MurrayE.C.GuzikB.BerryC.TouyzR.M.KreutzR.WangD.W.BhellaD.SaglioccoO.CreaF.ThomsonE.C.McInnesI.B.COVID-19 and the" exact="cardiovascular" post="system: implications for risk assessment, diagnosis, and treatment optionsCardiovasc."/>
  <result pre="J. Pediatr.87202043344210.1007/s12098-020-03292-132338347 169VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.SeidahN.G.NicholS.T.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol. J.220056910.1186/1743-422X-2-6916115318 170ZouL.DaiL.ZhangX.ZhangZ.ZhangZ.Hydroxychloroquine and chloroquine: a potential and"/>
  <result pre="Xia, Arbidol combined with LPV/r versus LPV/r alone against Coronavirus" exact="disease" post="2019: q retrospective cohort study, J. Infect. 81 (2020)"/>
  <result pre="patentPatent US01273962004 177RemacleA.G.GawlikK.GolubkovV.S.CadwellG.W.LiddingtonR.C.CieplakP.MillisS.Z.DesjardinsR.RouthierS.YuanX.W.NeugebauerW.A.DayR.StronginaA.Y.Selective and potent furin inhibitors protect cells from" exact="anthrax" post="without significant toxicityInt. J. Biochem. Cell Biol.42201098799510.1016/j.biocel.2010.02.01320197107 178PettersenE.F.GoddardT.D.HuangC.C.CouchG.S.GreenblattD.M.MengE.C.FerrinT.E.UCSF Chimeraâ€&quot;a"/>
 </snippets>
</snippetsTree>
